Non-alcoholic fatty liver disease and COVID-19: Harmless companions or disease intensifier?

World J Gastroenterol. 2023 Jan 14;29(2):367-377. doi: 10.3748/wjg.v29.i2.367.

Abstract

The pandemics of coronavirus disease 2019 (COVID-19) and non-alcoholic fatty liver disease (NAFLD) coexist. Elevated liver function tests are frequent in COVID-19 and may influence liver damage in NAFLD, while preexisting liver damage from NAFLD may influence the course of COVID-19. However, the prognostic relevance of this interaction, though, is unclear. Obesity is a risk factor for the presence of NAFLD as well as a severe course of COVID-19. Cohort studies reveal conflicting results regarding the influence of NAFLD presence on COVID-19 illness severity. Striking molecular similarities of cytokine pathways in both diseases, including postacute sequelae of COVID-19, suggest common pathways for chronic low-activity inflammation. This review will summarize existing data regarding the interaction of both diseases and discuss possible mechanisms of the influence of one disease on the other.

Keywords: COVID-19; Fatty liver; Inflammation; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Postacute sequelae of COVID-19.

Publication types

  • Review

MeSH terms

  • COVID-19* / complications
  • COVID-19* / metabolism
  • Humans
  • Inflammation / metabolism
  • Liver / metabolism
  • Non-alcoholic Fatty Liver Disease* / complications
  • Non-alcoholic Fatty Liver Disease* / diagnosis
  • Non-alcoholic Fatty Liver Disease* / epidemiology
  • Obesity / complications
  • Obesity / epidemiology
  • Obesity / metabolism
  • Risk Factors